Granules India receives official 2025 CDP rating

The company had achieved the highest "A" rating in Climate Change

Granules Life Sciences facility receives EIR from USFDA

This approval confirms the facility's compliance with FDA quality standards and regulatory requirements

Granules’ packaging facility in US completes FDA inspection with zero observations

Granules Consumer Health serves as Granules’ front-end division for OTC products in the US

Granules India opens advanced Centres of Excellence in Hyderabad

Ascelis Center of Excellence for Peptide Development and Characterization will drive the development of cosmetic, therapeutic, and pharmaceutical peptides

Granules Life Sciences receives first FDA approval for Hyderabad facility

Granules India’s facility secures FDA EIR with 'VAI’

The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection conducted in June 2025

Granules India and NIPER S.A.S Nagar launch CoE for sustainable pharma innovation

It will focus on interface between API and formulation manufacturing, reducing carbon footprint in formulation production, creating intellectual property, training next-generation scientists, and setting new industry benchmarks

Granules India Q1 FY26 PAT slips to Rs. 112.6 Cr

Granules India CEO K V Sitaram Rao resigns

Dr. Rao has over 29 years of experience in manufacturing, R&D, business operations, and customer service

Briefs: Neuland Laboratories and Granules India

Granules India receives 1 observation from USFDA for Chantilly facility